[iframe https://s.tradingview.com/embed-widget/symbol-info/?locale=in&symbol=ALT #%7B%22symbol%22%3A%22A%22%2C%22width%22%3A%22100%25%22%2C%22colorTheme%22%3A%22light%22%2C%22isTransparent%22%3Atrue%2C%22height%22%3A203%2C%22utm_source%22%3A%22themarketstracker.com%22%2C%22utm_medium%22%3A%22widget_new%22%2C%22utm_campaign%22%3A%22symbol-info%22%7D 900 250 ]

[iframe https://api.stockdio.com/visualization/financial/charts/v1/PricesChange?app-key=F086EEE750E14D8D8A456DB88B2D6D8C&symbol=ALT &conditionalVolume=false&allowPeriodChange=false&tooltipsStyle=None&palette=Financial-Light&showBorderAndTitle=false 300 200 ]

Float Short %

23.32

Margin Of Safety %

Put/Call OI Ratio

0.17

EPS Next Q Diff

-0.93

EPS Last/This Y

0.36

EPS This/Next Y

-0.27

Price

4.38

Target Price

19.75

Analyst Recom

1.7

Performance Q

-5.81

Upside

-417.6%

Beta

0.12

Ticker: ALT

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-23	ALT	5.5	0.13	0.08	140503
2026-01-26	ALT	5.65	0.14	0.09	150038
2026-01-27	ALT	6.16	0.14	0.10	152365
2026-01-28	ALT	5.11	0.14	0.21	159343
2026-01-29	ALT	5.09	0.15	0.28	162361
2026-01-30	ALT	5.61	0.16	0.15	163610
2026-02-02	ALT	5.54	0.17	0.28	141479
2026-02-03	ALT	5.47	0.18	0.24	144148
2026-02-04	ALT	5.12	0.18	0.62	146391
2026-02-05	ALT	4.91	0.18	0.08	147493
2026-02-06	ALT	4.86	0.18	0.12	149658
2026-02-09	ALT	4.68	0.16	0.44	142632
2026-02-10	ALT	4.66	0.16	0.35	145568
2026-02-11	ALT	4.62	0.17	0.01	147736
2026-02-12	ALT	4.55	0.16	0.39	149678
2026-02-13	ALT	4.54	0.16	0.05	149770
2026-02-17	ALT	4.51	0.16	0.16	146108
2026-02-18	ALT	4.47	0.16	0.65	148129
2026-02-19	ALT	4.48	0.17	0.21	150379
2026-02-20	ALT	4.39	0.17	0.04	152722
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-23	ALT	5.50	26.4	-92.3	-0.98
2026-01-26	ALT	5.66	26.4	-94.3	-0.98
2026-01-27	ALT	6.17	26.4	-109.8	-0.98
2026-01-28	ALT	5.11	26.4	-44.5	-0.98
2026-01-29	ALT	5.09	26.4	-86.3	-0.98
2026-01-30	ALT	5.61	26.8	-111.4	-0.98
2026-02-02	ALT	5.55	26.4	-83.6	-0.98
2026-02-03	ALT	5.48	26.4	-86.1	-0.98
2026-02-04	ALT	5.12	26.4	-	-0.98
2026-02-05	ALT	4.91	26.4	-	-0.98
2026-02-06	ALT	4.87	26.4	-	-0.98
2026-02-09	ALT	4.68	26.4	-	-0.98
2026-02-10	ALT	4.66	26.4	-	-0.98
2026-02-11	ALT	4.63	26.4	-	-0.98
2026-02-12	ALT	4.56	26.4	-	-0.98
2026-02-13	ALT	4.55	26.4	-	-0.98
2026-02-17	ALT	4.51	26.4	-	-0.98
2026-02-18	ALT	4.47	26.4	-	-0.98
2026-02-19	ALT	4.49	26.4	-	-0.98
2026-02-20	ALT	4.38	26.4	-	-0.98
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-23	ALT	4.31	3.90	24.92
2026-01-26	ALT	4.31	3.89	24.92
2026-01-27	ALT	4.31	3.89	24.92
2026-01-28	ALT	4.31	3.89	25.49
2026-01-29	ALT	4.31	3.89	25.49
2026-01-30	ALT	4.31	3.89	25.49
2026-02-02	ALT	3.56	3.65	25.50
2026-02-03	ALT	3.16	3.65	25.51
2026-02-04	ALT	3.16	3.65	25.51
2026-02-05	ALT	3.16	3.65	25.51
2026-02-06	ALT	3.16	3.65	25.51
2026-02-09	ALT	3.16	5.85	25.52
2026-02-10	ALT	3.00	5.85	25.52
2026-02-11	ALT	3.00	5.85	23.36
2026-02-12	ALT	3.00	5.85	23.36
2026-02-13	ALT	3.00	5.85	23.36
2026-02-17	ALT	4.37	11.34	23.32
2026-02-18	ALT	3.62	11.34	23.32
2026-02-19	ALT	3.62	11.34	23.32
2026-02-20	ALT	3.62	11.34	23.32
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

[iframe https://widget.finnhub.io/widgets/historical-eps?symbol=ALT 589 360 ]

Last Quarter Act. EPS

0.67

Avg. EPS Est. Current Quarter

-0.24

Avg. EPS Est. Next Quarter

-0.26

Insider Transactions

3.62

Institutional Transactions

11.34

Beta

0.12

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

81.4

Max Drawdown 5-Year %

-90.7

Target Price

19.75

P/E

Forward P/E

PEG

P/S

27425.73

P/B

2.26

P/Free Cash Flow

EPS

-1.07

Average EPS Est. Cur. Y

-0.98

EPS Next Y. (Est.)

-1.25

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-419575

Relative Volume

0.84

Return on Equity vs Sector %

-74.2

Return on Equity vs Industry %

-56.8

EPS 1 7Days Diff

EPS 1 30Days Diff

0.01

EBIT Estimation

[iframe https://widget.finnhub.io/widgets/recommendation?symbol=ALT 589 450 ]

[iframe https://widget.finnhub.io/widgets/eps-estimate?symbol=ALT 589 450 ]

Altimmune, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 59

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

stock quote shares ALT – Altimmune Inc Stock Price stock today

news today ALT – Altimmune Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch ALT – Altimmune Inc yahoo finance google finance

stock history ALT – Altimmune Inc invest stock market

stock prices ALT premarket after hours

ticker ALT fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: ALT

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y